

# John W Mellors

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/4185453/john-w-mellors-publications-by-year.pdf>

**Version:** 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

118 papers	6,412 citations	35 h-index	79 g-index
130 ext. papers	8,167 ext. citations	8.5 avg, IF	5.69 L-index

#	Paper	IF	Citations
118	Assessment of Clinical Outcomes Among Children and Adolescents Hospitalized With COVID-19 in 6 Sub-Saharan African Countries.. <i>JAMA Pediatrics</i> , <b>2022</b> ,	8.3	5
117	A highly-specific fully-human antibody and CAR-T cells targeting CD66e/CEACAM5 are cytotoxic for CD66e-expressing cancer cells in vitro and in vivo. <i>Cancer Letters</i> , <b>2022</b> , 525, 97-107	9.9	0
116	The transformation of HIV therapy: One pill once a day.. <i>Antiviral Therapy</i> , <b>2022</b> , 27, 13596535211062396.6	11.6	1
115	Cost-effectiveness of easy-access, risk-informed oral pre-exposure prophylaxis in HIV epidemics in sub-Saharan Africa: a modelling study.. <i>Lancet HIV,the</i> , <b>2022</b> , 9, e353-e362	7.8	2
114	Assessing the Suitability of Next-Generation Viral Outgrowth Assays to Measure Human Immunodeficiency Virus 1 Latent Reservoir Size. <i>Journal of Infectious Diseases</i> , <b>2021</b> , 224, 1209-1218	7	6
113	HIV-1 drug resistance among individuals who seroconverted in the ASPIRE dapivirine ring trial. <i>Journal of the International AIDS Society</i> , <b>2021</b> , 24, e25833	5.4	0
112	Insertional activation of and by HIV-1 proviruses in T cell lymphomas. <i>Science Advances</i> , <b>2021</b> , 7, eabi8795.4.3	14.3	2
111	Novel Criteria for Diagnosing Acute and Early Human Immunodeficiency Virus Infection in a Multinational Study of Early Antiretroviral Therapy Initiation. <i>Clinical Infectious Diseases</i> , <b>2021</b> , 73, e643-e651	11.6	1
110	The emerging plasticity of SARS-CoV-2. <i>Science</i> , <b>2021</b> , 371, 1306-1308	33.3	51
109	Integration in oncogenes plays only a minor role in determining the in vivo distribution of HIV integration sites before or during suppressive antiretroviral therapy. <i>PLoS Pathogens</i> , <b>2021</b> , 17, e1009141	7.6	10
108	Early Emergence and Long-Term Persistence of HIV-Infected T-Cell Clones in Children. <i>MBio</i> , <b>2021</b> , 12,	7.8	5
107	Improving the Outcomes of Immunocompromised Patients With Coronavirus Disease 2019. <i>Clinical Infectious Diseases</i> , <b>2021</b> , 73, e1397-e1401	11.6	17
106	Tracking HIV-1-Infected Cell Clones Using Integration Site-Specific qPCR. <i>Viruses</i> , <b>2021</b> , 13,	6.2	2
105	The TLR7 agonist vesatolimod induced a modest delay in viral rebound in HIV controllers after cessation of antiretroviral therapy. <i>Science Translational Medicine</i> , <b>2021</b> , 13,	17.5	9
104	Comparison of methods to quantify inducible HIV-1 outgrowth. <i>Journal of Virus Eradication</i> , <b>2021</b> , 7, 100043	0.43	1
103	Can Broadly Neutralizing HIV-1 Antibodies Help Achieve an ART-Free Remission?. <i>Frontiers in Immunology</i> , <b>2021</b> , 12, 710044	8.4	2
102	Vesatolimod, a Toll-like Receptor 7 Agonist, Induces Immune Activation in Virally Suppressed Adults Living With Human Immunodeficiency Virus-1. <i>Clinical Infectious Diseases</i> , <b>2021</b> , 72, e815-e824	11.6	17

101	Selective Decay of Intact HIV-1 Proviral DNA on Antiretroviral Therapy. <i>Journal of Infectious Diseases</i> , <b>2021</b> , 223, 225-233	7	24
100	Preprocedural SARS-CoV-2 Testing to Sustain Medically Needed Health Care Delivery During the COVID-19 Pandemic: A Prospective Observational Study. <i>Open Forum Infectious Diseases</i> , <b>2021</b> , 8, ofab022	7	4
99	HIV-specific T cell responses reflect substantive in vivo interactions with antigen despite long-term therapy. <i>JCI Insight</i> , <b>2021</b> , 6,	9.9	9
98	Safety, uptake, and use of a dapivirine vaginal ring for HIV-1 prevention in African women (HOPE): an open-label, extension study. <i>Lancet HIV,the</i> , <b>2021</b> , 8, e87-e95	7.8	22
97	Antibody Responses After mRNA-Based COVID-19 Vaccination in Residential Older Adults: Implications for Reopening. <i>Journal of the American Medical Directors Association</i> , <b>2021</b> , 22, 1593-1598	5.9	14
96	SARS-CoV-2 Viremia is Associated with COVID-19 Severity and Predicts Clinical Outcomes. <i>Clinical Infectious Diseases</i> , <b>2021</b> ,	11.6	20
95	Intractable Coronavirus Disease 2019 (COVID-19) and Prolonged Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Replication in a Chimeric Antigen Receptor-Modified T-Cell Therapy Recipient: A Case Study. <i>Clinical Infectious Diseases</i> , <b>2021</b> , 73, e815-e821	11.6	52
94	Updated assessment of risks and benefits of dolutegravir versus efavirenz in new antiretroviral treatment initiators in sub-Saharan Africa: modelling to inform treatment guidelines. <i>Lancet HIV,the</i> , <b>2020</b> , 7, e193-e200	7.8	20
93	Intact HIV Proviruses Persist in Children Seven to Nine Years after Initiation of Antiretroviral Therapy in the First Year of Life. <i>Journal of Virology</i> , <b>2020</b> , 94,	6.6	8
92	HIV-1 viremia not suppressible by antiretroviral therapy can originate from large T cell clones producing infectious virus. <i>Journal of Clinical Investigation</i> , <b>2020</b> , 130, 5847-5857	15.9	31
91	Clinical Characteristics and Outcomes of Patients Hospitalized for COVID-19 in Africa: Early Insights from the Democratic Republic of the Congo. <i>American Journal of Tropical Medicine and Hygiene</i> , <b>2020</b> , 103, 2419-2428	3.2	46
90	Brief Report: Dipyridamole Decreases Gut Mucosal Regulatory T-Cell Frequencies Among People With HIV on Antiretroviral Therapy. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , <b>2020</b> , 85, 665-669	3.1	3
89	Diverse Human Immunodeficiency Virus-1 Drug Resistance Profiles at Screening for ACTG A5288: A Study of People Experiencing Virologic Failure on Second-line Antiretroviral Therapy in Resource-limited Settings. <i>Clinical Infectious Diseases</i> , <b>2020</b> , 71, e170-e177	11.6	3
88	Intact proviral DNA assay analysis of large cohorts of people with HIV provides a benchmark for the frequency and composition of persistent proviral DNA. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2020</b> , 117, 18692-18700	11.5	24
87	Automated Multireplicate Quantification of Persistent HIV-1 Viremia in Individuals on Antiretroviral Therapy. <i>Journal of Clinical Microbiology</i> , <b>2020</b> , 58,	9.7	5
86	A Randomized, Placebo-Controlled, Pilot Clinical Trial of Dipyridamole to Decrease Human Immunodeficiency Virus-Associated Chronic Inflammation. <i>Journal of Infectious Diseases</i> , <b>2020</b> , 221, 1598-1606 <sup>20</sup>	7	20
85	HIV Proviral Sequence Database: A New Public Database for Near Full-Length HIV Proviral Sequences and Their Meta-Analyses. <i>AIDS Research and Human Retroviruses</i> , <b>2020</b> , 36, 1-3	1.6	8
84	HIV-1 DNA decay is faster in children who initiate ART shortly after birth than later. <i>Journal of the International AIDS Society</i> , <b>2019</b> , 22, e25368	5.4	10

83	Two-way mobile phone intervention compared with standard-of-care adherence support after second-line antiretroviral therapy failure: a multinational, randomised controlled trial. <i>The Lancet Digital Health</i> , <b>2019</b> , 1, e26-e34	14.4	19
82	Blockade of the PD-1 axis alone is not sufficient to activate HIV-1 virion production from CD4+ T cells of individuals on suppressive ART. <i>PLoS ONE</i> , <b>2019</b> , 14, e0211112	3.7	13
81	Telemedicine and Infectious Diseases Practice: A Leap Forward or a Step Back?. <i>Open Forum Infectious Diseases</i> , <b>2019</b> , 6, ofz196	1	4
80	Dapivirine vaginal ring for HIV prevention: modelling health outcomes, drug resistance and cost-effectiveness. <i>Journal of the International AIDS Society</i> , <b>2019</b> , 22, e25282	5.4	6
79	Trends in Pretreatment HIV-1 Drug Resistance in Antiretroviral Therapy-naïve Adults in South Africa, 2000-2016: A Pooled Sequence Analysis. <i>EClinicalMedicine</i> , <b>2019</b> , 9, 26-34	11.3	29
78	Recommendations for analytical antiretroviral treatment interruptions in HIV research trials-report of a consensus meeting. <i>Lancet HIV</i> , <b>2019</b> , 6, e259-e268	7.8	87
77	Assessing intra-lab precision and inter-lab repeatability of outgrowth assays of HIV-1 latent reservoir size. <i>PLoS Computational Biology</i> , <b>2019</b> , 15, e1006849	5	13
76	Naïve CD4+ T Cells Harbor a Large Inducible Reservoir of Latent, Replication-competent Human Immunodeficiency Virus Type 1. <i>Clinical Infectious Diseases</i> , <b>2019</b> , 69, 1919-1925	11.6	44
75	Longitudinal changes in HIV DNA in HIV controllers: what do they mean?. <i>Journal of the International AIDS Society</i> , <b>2019</b> , 22, e25254	5.4	1
74	Third-line antiretroviral therapy in low-income and middle-income countries (ACTG A5288): a prospective strategy study. <i>Lancet HIV</i> , <b>2019</b> , 6, e588-e600	7.8	17
73	Allogeneic Hematopoietic Cell Transplant for HIV Patients with Hematologic Malignancies: The BMT CTN-0903/AMC-080 Trial. <i>Biology of Blood and Marrow Transplantation</i> , <b>2019</b> , 25, 2160-2166	4.7	15
72	A9 A method to obtain full-length HIV proviral sequences and their sites of integration. <i>Virus Evolution</i> , <b>2019</b> , 5,	3.7	78
71	A12 Modeling residual HIV replication and the emergence of drug resistance on ART. <i>Virus Evolution</i> , <b>2019</b> , 5,	3.7	78
70	Persistent HIV-1 Viremia on Antiretroviral Therapy: Measurement and Mechanisms. <i>Frontiers in Microbiology</i> , <b>2019</b> , 10, 2383	5.7	9
69	HIV Infected T Cells Can Proliferate Without Inducing Expression of the Integrated Provirus. <i>Frontiers in Microbiology</i> , <b>2019</b> , 10, 2204	5.7	21
68	Clones of infected cells arise early in HIV-infected individuals. <i>JCI Insight</i> , <b>2019</b> , 4,	9.9	35
67	HIV-1 in lymph nodes is maintained by cellular proliferation during antiretroviral therapy. <i>Journal of Clinical Investigation</i> , <b>2019</b> , 129, 4629-4642	15.9	44
66	Combined HIV-1 sequence and integration site analysis informs viral dynamics and allows reconstruction of replicating viral ancestors. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2019</b> , 116, 25891-25899	11.5	41

65	A Simpler and More Sensitive Single-Copy HIV-1 RNA Assay for Quantification of Persistent HIV-1 Viremia in Individuals on Suppressive Antiretroviral Therapy. <i>Journal of Clinical Microbiology</i> , <b>2019</b> , 57,	9.7	18
64	Reply to Suthar et al. <i>Journal of Infectious Diseases</i> , <b>2019</b> , 219, 673-674	7	
63	Cumulative Antiretroviral Exposure Measured in Hair Is Not Associated With Measures of HIV Persistence or Inflammation Among Individuals on Suppressive ART. <i>Journal of Infectious Diseases</i> , <b>2018</b> , 218, 234-238	7	14
62	Rapid decline of HIV-1 DNA and RNA in infants starting very early antiretroviral therapy may pose a diagnostic challenge. <i>Aids</i> , <b>2018</b> , 32, 629-634	3.5	17
61	Blood biomarkers of expressed and inducible HIV-1. <i>Aids</i> , <b>2018</b> , 32, 699-708	3.5	13
60	Achieving Viral Suppression in 90% of People Living With Human Immunodeficiency Virus on Antiretroviral Therapy in Low- and Middle-Income Countries: Progress, Challenges, and Opportunities. <i>Clinical Infectious Diseases</i> , <b>2018</b> , 66, 1487-1491	11.6	32
59	The Argument Against Testing for INSTI Resistance in Treatment Naive Patients. <i>Clinical Infectious Diseases</i> , <b>2018</b> , 66, 1820-1821	11.6	
58	Frequent cross-resistance to rilpivirine among subtype C HIV-1 from first-line antiretroviral therapy failures in South Africa. <i>Antiviral Chemistry and Chemotherapy</i> , <b>2018</b> , 26, 2040206618762985	3.5	5
57	The Control of HIV After Antiretroviral Medication Pause (CHAMP) Study: Posttreatment Controllers Identified From 14 Clinical Studies. <i>Journal of Infectious Diseases</i> , <b>2018</b> , 218, 1954-1963	7	77
56	Associations between HIV-1 DNA copy number, proviral transcriptional activity, and plasma viremia in individuals off or on suppressive antiretroviral therapy. <i>Virology</i> , <b>2018</b> , 521, 51-57	3.6	12
55	Lower pre-ART intra-participant HIV-1 pol diversity may not be associated with virologic failure in adults. <i>PLoS ONE</i> , <b>2018</b> , 13, e0190438	3.7	3
54	Reply to Kojima and Klausner. <i>Clinical Infectious Diseases</i> , <b>2018</b> , 67, 1469-1470	11.6	1
53	Single-cell analysis of HIV-1 transcriptional activity reveals expression of proviruses in expanded clones during ART. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2017</b> , 114, E3659-E3668	11.5	87
52	Clinical Trial of the Anti-PD-L1 Antibody BMS-936559 in HIV-1 Infected Participants on Suppressive Antiretroviral Therapy. <i>Journal of Infectious Diseases</i> , <b>2017</b> , 215, 1725-1733	7	146
51	Performance of Celera RUO integrase resistance assay across multiple HIV-1 subtypes. <i>Journal of Virological Methods</i> , <b>2017</b> , 241, 41-45	2.6	2
50	Proviruses with identical sequences comprise a large fraction of the replication-competent HIV reservoir. <i>PLoS Pathogens</i> , <b>2017</b> , 13, e1006283	7.6	137
49	Levels of HIV-1 persistence on antiretroviral therapy are not associated with markers of inflammation or activation. <i>PLoS Pathogens</i> , <b>2017</b> , 13, e1006285	7.6	99
48	Ongoing HIV Replication During ART Reconsidered. <i>Open Forum Infectious Diseases</i> , <b>2017</b> , 4, ofx173	1	38

47	No evidence of HIV replication in children on antiretroviral therapy. <i>Journal of Clinical Investigation</i> , <b>2017</b> , 127, 3827-3834	15.9	44
46	Objective Measurement of Inaccurate Condom Use Reporting Among Women Using Depot Medroxyprogesterone Acetate for Contraception. <i>AIDS and Behavior</i> , <b>2017</b> , 21, 2173-2179	4.3	12
45	HIV-1 persistence following extremely early initiation of antiretroviral therapy (ART) during acute HIV-1 infection: An observational study. <i>PLoS Medicine</i> , <b>2017</b> , 14, e1002417	11.6	122
44	Ex vivo activation of CD4+ T-cells from donors on suppressive ART can lead to sustained production of infectious HIV-1 from a subset of infected cells. <i>PLoS Pathogens</i> , <b>2017</b> , 13, e1006230	7.6	31
43	Treatment with integrase inhibitor suggests a new interpretation of HIV RNA decay curves that reveals a subset of cells with slow integration. <i>PLoS Pathogens</i> , <b>2017</b> , 13, e1006478	7.6	30
42	T-cell responses targeting HIV Nef uniquely correlate with infected cell frequencies after long-term antiretroviral therapy. <i>PLoS Pathogens</i> , <b>2017</b> , 13, e1006629	7.6	22
41	Impact of HLA Class I Alleles on Timing of HIV Rebound After Antiretroviral Treatment Interruption. <i>Pathogens and Immunity</i> , <b>2017</b> , 2, 431-445	4.9	9
40	Cost-effectiveness of Injectable Preexposure Prophylaxis for HIV Prevention in South Africa. <i>Clinical Infectious Diseases</i> , <b>2016</b> , 63, 539-47	11.6	15
39	Origin of Rebound Plasma HIV Includes Cells with Identical Proviruses That Are Transcriptionally Active before Stopping of Antiretroviral Therapy. <i>Journal of Virology</i> , <b>2016</b> , 90, 1369-76	6.6	92
38	Novel Assays for Measurement of Total Cell-Associated HIV-1 DNA and RNA. <i>Journal of Clinical Microbiology</i> , <b>2016</b> , 54, 902-11	9.7	63
37	Selection of Rilpivirine-Resistant HIV-1 in a Seroconverter From the SSAT 040 Trial Who Received the 300-mg Dose of Long-Acting Rilpivirine (TMC278LA). <i>Journal of Infectious Diseases</i> , <b>2016</b> , 213, 1013-7		34
36	Therapeutic Vaccination With Dendritic Cells Loaded With Autologous HIV Type 1-Infected Apoptotic Cells. <i>Journal of Infectious Diseases</i> , <b>2016</b> , 213, 1400-9	7	34
35	HIV-1 Virion Production from Single Inducible Proviruses following T-Cell Activation Ex Vivo. <i>Journal of Virology</i> , <b>2016</b> , 90, 1673-6	6.6	21
34	Which therapeutic strategy will achieve a cure for HIV-1?. <i>Current Opinion in Virology</i> , <b>2016</b> , 18, 14-9	7.5	42
33	Clonally expanded CD4+ T cells can produce infectious HIV-1 in vivo. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2016</b> , 113, 1883-8	11.5	225
32	The size of the expressed HIV reservoir predicts timing of viral rebound after treatment interruption. <i>Aids</i> , <b>2016</b> , 30, 343-53	3.5	159
31	How Much Do We Know about Drug Resistance Due to PrEP Use? Analysis of Experts' Opinion and Its Influence on the Projected Public Health Impact. <i>PLoS ONE</i> , <b>2016</b> , 11, e0158620	3.7	12
30	Multi-dose Romidepsin Reactivates Replication Competent SIV in Post-antiretroviral Rhesus Macaque Controllers. <i>PLoS Pathogens</i> , <b>2016</b> , 12, e1005879	7.6	14

29	Deciphering the Effects of Injectable Pre-exposure Prophylaxis for Combination Human Immunodeficiency Virus Prevention. <i>Open Forum Infectious Diseases</i> , <b>2016</b> , 3, ofw125	1	7
28	A Cure for HIV Infection: "Not in My Lifetime" or "Just Around the Corner"? <i>Pathogens and Immunity</i> , <b>2016</b> , 1, 154-164	4.9	28
27	Retrovirus Integration Database (RID): a public database for retroviral insertion sites into host genomes. <i>Retrovirology</i> , <b>2016</b> , 13, 47	3.6	25
26	International AIDS Society global scientific strategy: towards an HIV cure 2016. <i>Nature Medicine</i> , <b>2016</b> , 22, 839-50	50.5	303
25	Ultrasensitive single-genome sequencing: accurate, targeted, next generation sequencing of HIV-1 RNA. <i>Retrovirology</i> , <b>2016</b> , 13, 87	3.6	30
24	Pretreatment HIV Drug Resistance and HIV-1 Subtype C Are Independently Associated With Virologic Failure: Results From the Multinational PEARLS (ACTG A5175) Clinical Trial. <i>Clinical Infectious Diseases</i> , <b>2015</b> , 60, 1541-9	11.6	51
23	Viremic relapse after HIV-1 remission in a perinatally infected child. <i>New England Journal of Medicine</i> , <b>2015</b> , 372, 786-8	59.2	188
22	Early Antiretroviral Therapy in South African Children Reduces HIV-1-Infected Cells and Cell-Associated HIV-1 RNA in Blood Mononuclear Cells. <i>Journal of Infectious Diseases</i> , <b>2015</b> , 212, 39-43	7	40
21	Low Frequency of Drug-Resistant Variants Selected by Long-Acting Rilpivirine in Macaques Infected with Simian Immunodeficiency Virus Containing HIV-1 Reverse Transcriptase. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2015</b> , 59, 7762-70	5.9	10
20	Well-mixed plasma and tissue viral populations in RT-SHIV-infected macaques implies a lack of viral replication in the tissues during antiretroviral therapy. <i>Retrovirology</i> , <b>2015</b> , 12, 93	3.6	16
19	Reversal of T-cell exhaustion as a strategy to improve immune control of HIV-1. <i>Aids</i> , <b>2015</b> , 29, 1911-5	3.5	10
18	Simian Immunodeficiency Virus SIV <sub>SA</sub> Infection of Rhesus Macaques as a Model of Complete Immunological Suppression with Persistent Reservoirs of Replication-Competent Virus: Implications for Cure Research. <i>Journal of Virology</i> , <b>2015</b> , 89, 6155-60	6.6	9
17	E138A in HIV-1 reverse transcriptase is more common in subtype C than B: implications for rilpivirine use in resource-limited settings. <i>Antiviral Research</i> , <b>2014</b> , 107, 31-4	10.8	48
16	Molecular mechanism of HIV-1 resistance to 3Pazido-2 $\beta$ 3Pdideoxyguanosine. <i>Antiviral Research</i> , <b>2014</b> , 101, 62-7	10.8	3
15	High Prevalence of Cross-resistance to Rilpivirine in Subtype C HIV-1 Isolates from First-line ART Failures in South Africa. <i>AIDS Research and Human Retroviruses</i> , <b>2014</b> , 30, A166-A166	1.6	3
14	HIV-1 DNA decay dynamics in blood during more than a decade of suppressive antiretroviral therapy. <i>Clinical Infectious Diseases</i> , <b>2014</b> , 59, 1312-21	11.6	153
13	Quantification of HIV-1 latency reversal in resting CD4+ T cells from patients on suppressive antiretroviral therapy. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2014</b> , 111, 7078-83	11.5	169
12	Impact of chemotherapy for HIV-1 related lymphoma on residual viremia and cellular HIV-1 DNA in patients on suppressive antiretroviral therapy. <i>PLoS ONE</i> , <b>2014</b> , 9, e92118	3.7	14

11	Improved single-copy assays for quantification of persistent HIV-1 viremia in patients on suppressive antiretroviral therapy. <i>Journal of Clinical Microbiology</i> , <b>2014</b> , 52, 3944-51	9.7	70
10	Lack of detectable HIV-1 molecular evolution during suppressive antiretroviral therapy. <i>PLoS Pathogens</i> , <b>2014</b> , 10, e1004010	7.6	156
9	Histone deacetylase inhibitor romidepsin induces HIV expression in CD4 T cells from patients on suppressive antiretroviral therapy at concentrations achieved by clinical dosing. <i>PLoS Pathogens</i> , <b>2014</b> , 10, e1004071	7.6	201
8	Discovery of a small molecule agonist of phosphatidylinositol 3-kinase p110 $\alpha$ that reactivates latent HIV-1. <i>PLoS ONE</i> , <b>2014</b> , 9, e84964	3.7	16
7	Persistence of viral reservoirs in multiple tissues after antiretroviral therapy suppression in a macaque RT-SHIV model. <i>PLoS ONE</i> , <b>2013</b> , 8, e84275	3.7	29
6	New tools for quantifying HIV-1 reservoirs: plasma RNA single copy assays and beyond. <i>Current HIV/AIDS Reports</i> , <b>2012</b> , 9, 91-100	5.9	21
5	Planning for pre-exposure prophylaxis to prevent HIV transmission: challenges and opportunities. <i>Journal of the International AIDS Society</i> , <b>2010</b> , 13, 24	5.4	38
4	Simplification Strategies to Reduce Antiretroviral drug Exposure: Progress and Prospects. <i>Antiviral Therapy</i> , <b>2009</b> , 14, 1-12	1.6	29
3	Lytic granule loading of CD8+ T cells is required for HIV-infected cell elimination associated with immune control. <i>Immunity</i> , <b>2008</b> , 29, 1009-21	32.3	417
2	Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. <i>New England Journal of Medicine</i> , <b>1997</b> , 337, 734-9	59.2	1610
1	Temporal Changes in Clinical Practice with COVID-19 Hospitalized Patients: Potential Explanations for Better In-Hospital Outcomes		3